Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide

PharmacoEconomics

Volumn 27, Issue 10, 2009, Pages 873-886

  Liubao, Peng ^a   Xiaomin, Wan ^a   Chongqing, Tan ^a   Karnon, Jon ^b   Gannong, Chen ^c   Jianhe, Li ^a   Wei, Cui ^a   Xia, Luo ^a   Junhua, Cao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHINA; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS;

EID: 70349944496     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11314750-000000000-00000     Document Type: Article

References (55)

1. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimate for cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2: 37. Epub 2002 Dec 26 (Pubitemid 38851284)
2. National Cancer Institute. Breast cancer [online]. Available from URL: http://www.cancer.gov/cancertopics/types/breast [Accessed 2009 May 20]
3. Liu YX, Zheng SJ. The analysis of monitoring the situation of breast cancer 1999-2001 in Yichang. Maternal Child Health Care China 2003; 18 (10): 626
4. Liu S, Huang X-R, Yi Y. Changes of common risk factors in breast cancer in the past 20 years. West China Med J 2007; 22 (4): 729-730
5. Zhang ZQ, Li GC, Ye Z. The analysis of breast cancer trend in China. China Cancer 2000; 9: 454-455
6. McCormick S, Brody J, Brown P, et al. Public involvement in breast cancer research: an analysis and model for future research. Int J Health Serv 2004; 34: 625-646 (Pubitemid 39487734)
7. Yabroff KR, Brown R, Halpern M. Breast cancer epidemiology, prevention and costs of care: implications for disease management programmes. Dis Manage Health Outcomes 2000; 8: 197-210 (Pubitemid 30825710)
8. Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008; 109: 367-377 (Pubitemid 351644849)
9. Ministry of Health of the People's Republic of China. Statistical bulletin [online]. Available from URL: http://www.moh. gov.cn/publicfiles/ business/htmlfiles/mohbgt/s6689/200804/ 33525.htm [Accessed 2009 Jan 26]
10. Goldstein LJ, O'Neill A, Sparano JA, et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008; 26: 4092-4099
11. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positivenode breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496 (Pubitemid 20301179)
12. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 5381-5386
13. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009; 27 (8): 1177-1183
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-breast cancer 2008 [online]. Available from URL: http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf [Accessed 2008 Aug 1]
15. Griggs JJ, Sorbero ME. Cost effectiveness, chemotherapy, and the clinician. Breast Cancer Res Treat 2009; 114 (3): 597-598
16. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medical. JAMA 1996; 276: 1253-1258 (Pubitemid 26337709)
17. The People's Bank of China. Currency exchange rate table for Chinese yuan [online]. Available from URL: http://www.pbc. gov.cn/huobizhengce/ huobizhengcegongju/huilvzhengce/re nminbihuilvjiaoyishoupanjia.asp [Accessed 2009 Feb 4]
18. Doyle T, Schultz DJ, Peters C, et al. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiation Oncol Biol Phys 2001; 51: 74-80 (Pubitemid 32758864)
19. Janjan NA, McNeese MD, Buzdar AU, et al. Management of locoregional recurrent breast cancer. Cancer 1986; 58: 1552-1556 (Pubitemid 16016843)
20. Harris EE, Hwang WT, Seyednejad F, et al. Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 2003; 98: 2144-2151 (Pubitemid 37392417)
21. Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994; 12: 2071-2077 (Pubitemid 24356023)
22. Kamby C, Sengeløv L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer: a prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997; 45: 181-192
23. Schmoor C, Sauerbrei W, Bastert G, et al. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000; 18: 1696-1708 (Pubitemid 30220548)
24. Haylock BJ, Coppin CM, Jackson J, et al. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiation Oncology Biol Phys 2000; 46: 355-362 (Pubitemid 30067785)
25. Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002; 8: 81-87
26. Ries LAG, Young JL, Keel GE, et al., editors. SEER survival monograph: cancer survival among adults. US SEER program, 1988-2001 patient and tumor characteristics [NIH pub no. 07-6215]. Bethesda (MD): National Cancer Institute, 2007
27. WHO. 2006 Chinese women life table [online]. Available from URL: http://www.who.int/whosis/database/life-tables/life- tables.cfm [Accessed 2008 Mar 26]
28. Karnon J, Delea T, Johnston SR, et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006; 24 (3): 237-250 (Pubitemid 43374376)
29. Wolowacz SE, Cameron DA, Tate HC, et al. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 2008; 26: 925-933
30. Karnon J, Kerr GR, Jack W, et al. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007; 97: 479-485 (Pubitemid 47258450)
31. Will BP, Berthelot JM, Le Petit C, et al. Estimates of lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000; 36: 724-735 (Pubitemid 30179743)
32. Ward S, Simpson E, Davis S, et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007; 11 (40): 1-144 (Pubitemid 47260180)
33. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 157-177 (Pubitemid 16130640)
34. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
35. Appleby J, Devlin N, Parkin D. NICE's cost-effectiveness threshold. BMJ 2007; 335: 358-359
36. WHO. Cost-effectiveness thresholds [online]. Available from URL: http://www.who.int/choice/costs/CER-thresholds/en/ [Accessed 2009 Jan 27]
37. China economic census [online]. Available from URL: http://www.stats.gov. cn/zgjjpc/cgfb/t20060307-402309437. htm [Accessed 2009 May 8]
38. Liu J, Ling L, Zhao LL, et al. Evaluation and decision analysis of methadone maintenance treatment in Guangdong province. Chin J Health Stat 2007; 24: 501-504
39. Beijing statistical information net [online]. Available from URL: http://www.bjstats.gov.cn/ [Accessed 2009 Jan 27]
40. Shanghai tongji. Statistical bulletin [online]. Available from URL: http://www.stats-sh.gov.cn/2005shtj/index.asp [Accessed 2009 Jan 27]
41. Chen W, Lu XZ, Chen HY, et al. Economic evaluation of lamivudine in the treatment of chronic hepatitis B. Chin Hepatol 2005; 10: 73-75
42. Peng LB, Tan CQ, Wan XM. Cost-utility analysis in China: differences and difficulties compared with developed countries [letter]. Pharmacoeconomics 2007; 25 (7): 619
43. Nadler E, Eckert B, Peter J. Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11 (2): 90-95
44. Xinhua news [online]. Available from URL: http://news. xinhuanet.com/english/2008-10/14/content-10192875.htm [Accessed 2009 Mar 3]
45. Parry J, Weiyuan C. Making health care affordable in China. Bull World Health Organ 2008; 86 (11): 821-823
46. Government Work Report. The central people's government of the People's Republic of China [online]. Available from URL: http://www.gov.cn/2009lh/ content-1252563.htm [Accessed 2009 May 18]
47. Opinions of the CPC Central Committee and the State Council on Deepening the Health Care System Reform. National Development and Reform Commission [online]. Available from URL: http://shs.ndrc. gov.cn/ygjd/ygwj/t20090408- 271138.htm [Accessed 2009 May 18]
48. Chinese medical reform plan gives pharmacoeconomics a new mission. Pharmacoeconomics China [online]. Available from URL: http://www.pe-cn.org/en/ indexen.asp [Accessed 2009 Apr 29]
49. Verma S, Mittmann N, Bernard LM, et al. San Antonio Breast Cancer Symposium 2008. Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer? [online]. Available from URL: http://www.posters2view.com/sabcs08/viewp.php?nu=6105 [Accessed 2009 Jan 11]
50. Younis T, Rayson D, Skedgel C. Antonio Breast Cancer Symposium 2008. Adjuvant chemotherapy in breast cancer: is TC a cost-effective regimen compared to AC? [online]. Available from URL: http://www.posters2view.com/ sabcs08/viewp.php?nu=6110 [Accessed 2009 Jan 11]
51. Younis T, Rayson D, Sellon M, et al. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs FEC 100. Breast Cancer Res Treat 2008; 111: 261-267
52. Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat 2008; 109: 559-566 (Pubitemid 351692065)
53. Jiang Z, J, Wang T. Interpreting of NCCN practice guidelines in oncology: breast cancer [in Chinese]. Chinese J Surgery 2009; 7: 485-487
54. Lee SG, Jee YG, Chung HC, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluororacil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat 2009; 114 (3): 589-595
55. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352 (22): 2302-2313 (Pubitemid 40740554)